Skip to main content
      Meta-analysis of 3 RCTs (n=1990) shows IL-17i offers comparable joint response but superior skin clearance vs adalimumab

      Antoni Chan MD (Prof) synovialjoints

      4 months 1 week ago
      Meta-analysis of 3 RCTs (n=1990) shows IL-17i offers comparable joint response but superior skin clearance vs adalimumab in biologic-naive PsA. IL-17i also had fewer discontinuations due to adverse events. Supports sequencing of biologics through different mechanisms of action in https://t.co/SJgFUMxWVb
      IgG4-RD continues to present in new and unusual ways

      Hasbani et al. report 9 IgG4-RD patients with coronary artery invo

      Brian Jaros, MD Dr_Brian_MD

      4 months 1 week ago
      IgG4-RD continues to present in new and unusual ways Hasbani et al. report 9 IgG4-RD patients with coronary artery involvement RCA and LAD most affected Seen on CTA Majority received RTX 7/9 pt at least partially improved imaging on f/u @RheumNow #ACR25 Abst 2531 https://t.co/Na0gdq3dgb
      A new genetic score for ILD prediction! 🫁

      Developed in the Veterans RA cohort and Validation in a Swedish cohort

      Mo

      Aurelie Najm AurelieRheumo

      4 months 1 week ago
      A new genetic score for ILD prediction! 🫁 Developed in the Veterans RA cohort and Validation in a Swedish cohort Model using classic RA-ILD risk factors and a cocktail of genetic risk A cut off of 0.05 in this cohort would exclude 36% from HRCT or PFTs Good performance https://t.co/6UsoSQAtyK
      RESET-RA, RCT of vagus nerve stim (device that zaps pts in neck)

      Marginal improvements in ACR20 at wk 12; trend in to i

      Mike Putman EBRheum

      4 months 1 week ago
      RESET-RA, RCT of vagus nerve stim (device that zaps pts in neck) Marginal improvements in ACR20 at wk 12; trend in to improvement in unblinded part of study fwiw Have never seen result that is more likely to be driven by plbo effect & unblinding 🤪 @RheumNow #ACR25 Abstr#2278 https://t.co/BlR570nv7k
      Hindosh et al. Semaglutide associated with reduced synovitis, joint pain and swelling, in RA. @RheumNow #ACR25 Abstr#228

      Richard Conway RichardPAConway

      4 months 1 week ago
      Hindosh et al. Semaglutide associated with reduced synovitis, joint pain and swelling, in RA. @RheumNow #ACR25 Abstr#2286 https://t.co/6Xs4um5l32
      Late Breaker: Observational study of MEPO in EGPA

      375 pts receiving MEPO had less ARF/CKD than 727 pts receiving standa

      Mike Putman EBRheum

      4 months 1 week ago
      Late Breaker: Observational study of MEPO in EGPA 375 pts receiving MEPO had less ARF/CKD than 727 pts receiving standard of care Smallish event #'s & lots of p values... also, what about the vasculitis?!? #ACR25 @RheumNow AbstLB16 https://t.co/XwqNthfwPF
      Bremer et al. Earlier initiation of biosimilar adalimumab (vs csDMARDs) may result in cost-savings. Reduced cost of test

      Richard Conway RichardPAConway

      4 months 1 week ago
      Bremer et al. Earlier initiation of biosimilar adalimumab (vs csDMARDs) may result in cost-savings. Reduced cost of tests, consultations, and hospitalisations. @RheumNow #ACR25 Abstr#2271 https://t.co/lHaSiX3WLd
      Semaglutide isn’t just for weight loss?

      In RA, users had 20–40% lower risk of synovitis, stiffness & swelling u

      Jiha Lee JihaRheum

      4 months 1 week ago
      Semaglutide isn’t just for weight loss? In RA, users had 20–40% lower risk of synovitis, stiffness & swelling up to 1 year vs matched controls. GLP-1 agonists may offer anti-inflammatory benefit beyond metabolism. @RheumNow #ACR25 Abstract#2286
      PLEX continues to be OUT for DAH in AAV

      Retrospective review of ~1.4k AAV-DAH pt
      375 who received PLEX compared to thos

      Brian Jaros, MD Dr_Brian_MD

      4 months 1 week ago
      PLEX continues to be OUT for DAH in AAV Retrospective review of ~1.4k AAV-DAH pt 375 who received PLEX compared to those who did not PLEX tx patients: - higher odds of death - higher sepsis - increased LOS - increased hospitalization cost @RheumNow #ACR25 Abst 2517
      Mateo Faxas et al. TriNetX study, propensity score matched. 3000 patients. Arrythmia risk is higher with IL-6i vs TNFi i

      Richard Conway RichardPAConway

      4 months 1 week ago
      Mateo Faxas et al. TriNetX study, propensity score matched. 3000 patients. Arrythmia risk is higher with IL-6i vs TNFi in diabetic RA patients. V Tachy (HR 1.4), PPM need (HR 1.4) significantly higher. AF, SVT, VF all numerically increased. @RheumNow #ACR25 Abstr#2283 https://t.co/U2Tk38Mobg
      Heydari-Kamjani et al. TriNetX study. 28973 PsA patients. IL-17i and IL-23i lower rates stroke, MI, DVT/PE than TNFi. IL

      Richard Conway RichardPAConway

      4 months 1 week ago
      Heydari-Kamjani et al. TriNetX study. 28973 PsA patients. IL-17i and IL-23i lower rates stroke, MI, DVT/PE than TNFi. IL-12/23i higher rate of stroke vs TNFi. @RheumNow #ACR25 Abstr#2363 https://t.co/fNHaxyYPCP
      Adding social risk factors to the mix
      Abstract 1917: WashU Rheumatology examined SRF screening in the clinic
      🔹 50% s

      Akhil Sood MD, MS AkhilSoodMD

      4 months 1 week ago
      Adding social risk factors to the mix Abstract 1917: WashU Rheumatology examined SRF screening in the clinic 🔹 50% screened once; 1/3 screened > 1 🔹 Core SRFs (finance, transport, housing, food) relatively stable 🔹 Biggest change over time: stress @RheumNow #ACR25 https://t.co/oKlwMZ77nB
      Is taking NSAIDs +TNFi better for the joints?
      Abstract 2359: In radiographic axSpA, NSAIDS + TNFi associated with
      -fewe

      Akhil Sood MD, MS AkhilSoodMD

      4 months 1 week ago
      Is taking NSAIDs +TNFi better for the joints? Abstract 2359: In radiographic axSpA, NSAIDS + TNFi associated with -fewer syndesmophytes 36% vs 58% TNFi - no significant effect on hip structural changes - @RheumNow #ACR25
      The CAR T engine doesn’t stop!LB04: Phase 1 bispecific CD19/BCMA CAR T in refractory autoimmune disease 🚗💥✅

      Akhil Sood MD, MS AkhilSoodMD

      4 months 1 week ago

      The CAR T engine doesn’t stop! LB04: Phase 1 bispecific CD19/BCMA CAR T in refractory autoimmune disease 🚗💥 ✅ Low AEs (mostly Gr 1–2 CRS, hematologic) 💪 Robust efficacy in lupus nephritis 🔄 Deep B-cell depletion → naïve B-cell repopulation @RheumNow #ACR25

      ×